Choice of psoriasis treatment affects CVD event rates

September 27, 2012
Choice of psoriasis treatment affects CVD event rates
Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

(HealthDay)—Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

Ole Ahlehoff, M.D., of the Copenhagen University Hospital in Gentofte, Denmark, and colleagues conducted a real-world study involving 2,400 Danish patients with severe psoriasis treated with systemic anti-inflammatory drugs, including 693 patients treated with and 799 treated with methotrexate, to measure cardiovascular disease event rates. The primary outcome was a composite end point of death, , and stroke.

The researchers found that, overall, 6.0, 17.3, and 44.5 events per 1,000 patient-years occurred in patients treated with biologic agents, methotrexate, and other therapies, respectively. Using the other psoriatic therapies (including retinoids, cyclosporine, and phototherapy) as a reference cohort, the risk of cardiovascular events was lower with biologic agents (hazard ratio [HR], 0.28) and methotrexate (HR, 0.65).

"In conclusion, in this nationwide study of patients with severe psoriasis, systemic anti-inflammatory treatment with biological agents or methotrexate was associated with reduced cardiovascular disease event rates," the authors write. "Further studies are needed to confirm these findings and evaluate their clinical implications."

Several authors disclosed to the pharmaceutical industry.

Explore further: Study examines risk of heart attack associated with various psoriasis treatments

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Recommended for you

How do white blood cells move so fast?

November 22, 2016

If you fall and scrape a knee, it's the job of white blood cells called neutrophils to rush to the site of infection and chase down invading bacteria.

New treatment for allergic response targets mast cells

November 21, 2016

Researchers from North Carolina State University and the National Institutes of Health (NIH) have developed a method that stops allergic reactions by removing a key receptor from mast cells and basophils. Their work has implications ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.